Mayr-melnhof Karton AG Overview
MM Group is one of Europe's leading producers of cartonboard and folding cartons, and among the few players that are fully integrated from pulp and board mills to converted packaging. Its Board & Paper division produces about 3.1 million tonnes a year of recycled-fibre and virgin-fibre cartonboard, kraft and uncoated fine papers, and pulp across mills in Austria, Germany, Slovenia, Poland and Finland. Its two packaging divisions convert board into folding cartons for food, confectionery, premium consumer goods and pharmaceuticals; the pharma division also makes leaflets and labels. The group is controlled by the Mayr-Melnhof and allied core families, who hold about 58–60%. It is now in a cost-led transformation called "Fit-For-Future", after a debt-funded expansion in 2021–22 was followed by a structural downturn in European board markets. MM's investment case rests on three things: high-quality packaging franchises with mid-teens adjusted EBITDA margins, a recovery option in a currently sub-scale-margin board business, and a strengthening balance sheet.
What the company does
MM manufactures fibre-based consumer packaging along most of the value chain:
-
Fibre and board production (MM Board & Paper). The division produces chemical pulp and CTMP in Poland and Finland, recycled-fibre cartonboard (white-lined chipboard, WLC) in Austria, Germany and Slovenia, virgin-fibre folding boxboard (FBB) and solid bleached board (SBB) in Poland and Finland, plus coated liner, uncoated fine paper, kraft papers and market pulp.
- In FY2025 the division produced 3,138 kt: 1,758 kt cartonboard (incl. coated liner), 505 kt paper and 875 kt pulp, of which 126 kt was market pulp.
-
Conversion into folding cartons and related printed products (MM Food & Premium Packaging; MM Pharma & Healthcare Packaging). These divisions print, die-cut, emboss, fold and glue cartons for brand owners in food, confectionery, cereals, frozen foods, beverages, tobacco/premium consumer goods, personal care and pharmaceuticals.
-
The pharma division also produces patient leaflets, labels and booklet labels.
-
Packaging output in FY2025 was 2,541 million m² in Food & Premium (2,172 million m² excluding TANN) and 897 million m² in Pharma & Healthcare.
-
Business and revenue model
Revenue model: Almost entirely product sales. There is no material subscription, licensing or service revenue.
-
Board & Paper sells board and paper by the tonne to independent converters and to MM's own packaging plants. Inter-divisional sales are eliminated on consolidation: segment sales summed to EUR 4,086.9 m against group sales of EUR 3,885.3 m in FY2025, implying about EUR 201.6 m of eliminations (computed from S1).
-
Packaging divisions sell to brand owners under framework and long-term supply contracts. Both packaging divisions announced several new long-term agreements with key customers in H1 2026.
Pricing dynamics: - Board and paper prices are cyclical and set by European supply and demand, import pressure and input costs (wood, recovered paper, energy, chemicals).
-
Packaging pricing is contract-based and generally includes some form of cost pass-through, which makes packaging margins structurally more stable than board margins.
-
This stability is visible in the numbers: the FY2025 adjusted operating margin was 10.2% in Food & Premium versus 0.2% in Board & Paper.
Value-chain position: MM is upstream (pulp/board) plus midstream (converting). Its customers are converters, which are sometimes competitors of its own packaging divisions, and global FMCG and pharma brand owners. MM does not own forests; wood is procured externally. Wood pricing from Polish state forests was cited as uncompetitive in the Kwidzyn context.
Customer types and end markets
| End market | Served by | Notes |
|---|---|---|
| Food (dry, frozen, chilled), cereals, bakery | FPP, B&P | Core folding-carton volumes; plastic-to-fibre substitution is an innovation focus |
| Confectionery, beverages, tea/coffee | FPP | Premium print finishing |
| Premium / luxury consumer goods, cosmetics | FPP | Luxury packaging plants, e.g. in France |
| Tobacco packaging (cigarette cartons) | FPP | Historically important. Tipping paper (TANN) was divested in 2025. |
| Pharmaceuticals and healthcare (cartons, leaflets, labels) | PHP | Growth in North America and Ireland; strong demand linked to GLP-1 applications |
| Independent converters / folding-carton makers | B&P | More than 90% of folding boxboard sales volume is in Europe (H1 2026, S2) |
| Office / graphic papers, packaging kraft paper | B&P (Kwidzyn, Kotka) | Uncoated fine paper "in sharp decline" in 2025. Packaging kraft paper capacity is being expanded at Kwidzyn. |
| Market pulp | B&P | 126 kt in FY2025 |
Company self-description
In its 2026 releases, MM describes itself as a global leader in consumer packaging. It cites cartonboard and folding cartons as its core, complemented by kraft papers, uncoated fine papers, leaflets and labels. Its stated objective is to uphold cost, technology and innovation leadership in cartonboard packaging.
Independent characterisation
MM is best understood as two businesses under one roof:
A high-quality European folding-carton converter: spanning food/premium and pharma. In H1 2026 it delivered a combined adjusted EBITDA of EUR 143.5 m at a 14.3% margin in both packaging divisions.
A cyclical, capital-intensive board and paper producer: It carried EUR 1.85–1.89 bn of capital employed (more than half of group capital employed) but earned a negative to near-zero adjusted ROCE in 2024–H1 2026.
The 2021 acquisitions of Kwidzyn and Kotkamills made MM a major virgin-fibre producer just as European FBB capacity expanded and US exports returned to Europe. That timing explains much of the subsequent profit collapse.
The equity story is therefore one of self-help (Fit-For-Future), portfolio focus (the TANN exit, closures) and optionality on a board-cycle recovery.
Strategy
Stated strategy (themes from the FY2025 and H1 2026 reports)
-
Cost, technology and innovation leadership in cartonboard packaging, the self-described core.
-
Portfolio focus on consumer packaging:
-
Exit non-core businesses (TANN, sold because tipping paper is unrelated to cartonboard and consumer packaging).
-
Prune sub-scale plants (Bangor, Leeuwarden, Karaman, Sarreguemines).
-
Make selective core investments (Arnsberg).
-
-
Fit-For-Future transformation programme: a group-wide programme for structural earnings improvement.
-
Balanced three-division positioning: a well-invested asset base and solid financing.
-
Sustainability as a commercial differentiator:
-
Decarbonisation, water efficiency, biodiversity, waste prevention and occupational safety.
-
CDP triple A; EcoVadis Platinum.
-
-
Growth niches:
-
Pharma (US, GLP-1-related applications).
-
Plastic-to-fibre substitution in food packaging.
-
Fit-For-Future programme: targets and delivery
| Milestone | Target / outcome | Source |
|---|---|---|
| Programme launch (2025) | More than EUR 150 m earnings uplift by 2027 versus 2024 | S1 |
| FY2025 results (Mar 2026) | More than EUR 250 m uplift in 2027 versus 2024 (excl. TANN and market effects); about EUR 70 m delivered in 2025 | S1 |
| H1 2026 results (Aug 2026) | Target raised to more than EUR 330 m cumulative by 2027 versus 2024 excl. TANN; EUR 105 m delivered in H1 2026; more than EUR 100 m expected in H2 2026 | S2 |
| One-off costs | EUR 29.0 m (FY2025); EUR 22.9 m (H1 2026) | S1, S2 |
Strategic initiatives in the last 24 months
| Initiative | Date | Detail | Source |
|---|---|---|---|
| Sale of TANN Group | Agreed Dec 2024; closed Jun 2025 | EUR 360 m EV; about EUR 220 m sales; EUR 125.1 m gain | S1, S10 |
| Share buyback | Jan–Dec 2025 | 569,019 shares, EUR 41.2 m | S11 |
| New dividend policy | Mar 2026 | Payout of 40–60% of profit, subject to leverage corridors, capex needs and dividend continuity (previously one-third of profit) | S1 |
| Kwidzyn efficiency package | Completion autumn 2026 | About EUR 100 m: continuous pulp digester (lower energy use, CO2 and wood cost), winder and transport modernisation, new sheeter. About EUR 30 m annual earnings contribution from 2027. CO2 at the mill to fall by about one-third. | S1, S2 |
| Kotka electric boilers | Spring 2027 | Significant CO2 reduction | S1 |
| Romania packaging expansion | Commercial production Oct 2026 | Capacity for new business onboarding | S1, S2 |
| US pharma expansion | Contribution from 2027 | Growth capex | S2 |
| PHP South-West Europe restructuring | 2,025 | EUR 15.2 m footprint charges (France, Spain) | S1 |
| Arnsberg acquisition | Signed Aug 2026; closing Q4 2026 | 230 kt recycled board; turnaround via synergies | S7 |
| Reporting streamlining | From Q1 2026 | Q1 and Q3 reported as trading statements only | S6 |
| Management Board expansion | Sep 2026 | Five members, adding divisional heads | S8 |
Guidance and medium-term framework
2026 outlook:
-
Challenging business environment, with subdued consumer demand and higher transport, energy, chemical, wood and recovered-paper costs.
-
Q3 2026 maintenance standstills at Kwidzyn and Kotka (about EUR 35 m impact).
-
Partial offsets: slightly improved prices for selected board and paper grades, continued growth in selected pharma and consumer applications, and more than EUR 100 m of Fit-For-Future contribution in H2.
Capex: about EUR 250 m in 2026.
Financial framework: net debt/equity 35–55% and net debt/adjusted EBITDA 1.5–2.5x.
Explicit numeric EBITDA, EPS or margin guidance for 2026: not provided.
Products & Services
MM does not publish list prices. Pricing is negotiated per tonne for board and per contract for cartons. MM's releases do not give launch years for most individual grades. Brand names below are given where verified; others are marked.
MM Board & Paper
| Product line | Description / specifications | Target customer | Production base | Notes |
|---|---|---|---|---|
| Recycled-fibre cartonboard (WLC / GD/GT grades), incl. TOPCOLOR® | Coated recycled board for folding cartons. TOPCOLOR is an MM recycled-board brand (pictured in Aug 2026 trade coverage). | Folding-carton converters; food, household and non-food packaging | Frohnleiten (AT), Neuss (DE), Gernsbach (DE), Kolicevo (SI) | Market "relatively resilient" in 2025–H1 2026. Arnsberg (DE, about 230 kt, liner focus) to be added from Q4 2026. |
| Coated liner (recycled) | Liner products for laminated / corrugated applications | Corrugated and laminating converters | Recycled mills; Arnsberg specialises in liner | Included in cartonboard tonnage |
| Virgin-fibre folding boxboard (FBB) | Lightweight, high-bulk primary-fibre board for food, pharma and premium packaging | Brand owners and converters requiring primary fibre | MM Kwidzyn (PL), MM Kotkamills (FI) | Under pressure from new European capacity, returning US exports and Asian imports |
| Solid bleached board (SBB) | Premium bleached board | Premium / luxury and pharma packaging | Kotkamills / Kwidzyn | Included in folding-carton board tonnage (S2 footnote) |
| Food-service and barrier boards (Kotkamills legacy portfolio) | Cup / food-service board and dispersion-barrier boards for plastic replacement | Food-service and cup converters | Kotka (FI) | Specific brand names (e.g. ISLA, AEGLE) are not re-verified for current MM branding |
| Uncoated fine paper (UFP) | Office, copy and graphic papers in reels and cut-size | Paper merchants, offices, printers | Kwidzyn (PL) | Market "in sharp decline" in 2025. A new sheeter and modernised winders are increasing reel-format flexibility. |
| Packaging kraft paper (PKP) | Kraft paper for flexible and paper packaging | Packaging converters | Kwidzyn (PL); Kotka (FI) | Capacity and flexibility increased via the 2026 Kwidzyn projects. Sack kraft was discontinued at Kwidzyn. |
| Saturating / absorbent kraft (Kotkamills legacy) | Kraft for decorative laminates | Laminate producers | Kotka (FI) | — |
| Market pulp | Chemical pulp and CTMP not used internally | Paper and board producers | Kwidzyn, Kotka | 126 kt in FY2025; 45 kt in H1 2026 |
| Metric | FY2024 | FY2025 |
|---|---|---|
| Cartonboard incl. coated liner (kt) | 1,763 | 1,758 |
| Paper (kt) | 497 | 505 |
| Pulp total (kt) | 885 | 875 |
| Market pulp (kt) | 119 | 126 |
| Total tonnage produced (kt) | 3,145 | 3,138 |
Volume profile (kt produced):
Source: S1. H1 2026 tonnage was 1,645 kt, of which 936 kt folding-carton board, 262 kt paper and 447 kt pulp.
MM Food & Premium Packaging
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Food folding cartons | Printed and converted cartons for dry, chilled and frozen foods, cereals and bakery | Global and regional FMCG brand owners | Largest volume line. Innovation focus on replacing plastic with fibre-based alternatives. |
| Confectionery and beverage packaging | High-graphics cartons, multipacks, gift boxes | Confectionery and beverage brands | Premium finishing (embossing, hot-foil, special coatings) |
| Premium / luxury packaging | Rigid and folding luxury boxes for cosmetics, spirits and fragrances | Luxury brand houses | Luxury packaging plants in France |
| Tobacco packaging | Cigarette cartons and inner frames | Tobacco majors | Long-standing franchise. Tipping paper (TANN; about EUR 220 m sales, 7 sites, about 730 staff) was sold in 2025. |
| Personal-care and household cartons | Folding cartons for HPC products | HPC brand owners | — |
| Metric | FY2024 | FY2025 |
|---|---|---|
| FPP produced volume incl. TANN (million m2) | 3,103 | 2,541 |
| FPP produced volume excl. TANN (million m2) | 2,240 | 2,172 |
Volume (million m², produced):
Source: S1.
Capacity actions:
-
Technological expansion of the Romania plant, with commercial production scheduled from October 2026.
-
Superpak Karaman (Turkey) closed, with business concentrated at the remaining two Turkish plants.
-
Bangor (UK) and Leeuwarden (NL) sold.
-
Two plants in the Middle East contributed about 2% of group sales and about 6% of group adjusted EBITDA in 2025. MM warned of expected business interruptions in March 2026.
MM Pharma & Healthcare Packaging
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Pharma folding cartons | Secondary packaging with serialisation and tamper-evidence features | Big pharma, generics, OTC, CDMOs | GLP-1 related demand supported H1 2026 growth |
| Patient information leaflets | Folded leaflets, high-speed multi-panel | Pharma manufacturers | French leaflet plants include L'Isle d'Espagnac and Soyaux. Sarreguemines (523 m units/yr) closed. |
| Labels and booklet labels | Pressure-sensitive and multi-page labels | Pharma and healthcare | Part of the Essentra Packaging heritage |
| Healthcare / consumer health packaging | Cartons for medical devices and consumer health | Healthcare companies | — |
Volume: 918 million m² in FY2024 and 897 million m² in FY2025. H1 2026: 470 million m², up 1.1%.
Growth investments: Expansion investments in the US are on schedule and expected to contribute from 2027.
Financial Narrative
Income statement
Basis and sources:
-
FY2021–22: S5. FY2023: S4. FY2024: S3. FY2025: S1.
-
"EBITDA, headline basis" is reported EBITDA for FY2021–22 and adjusted EBITDA for FY2023–25 (FY2024 reported equals adjusted).
-
FY2025 reported EBITDA was EUR 517.0 m, including the TANN gain.
-
FY2021 revenue growth is computed from the 2020 sales of EUR 2,528 m (aggregator, S17).
-
Diluted EPS equals basic EPS. No dilutive instruments were disclosed in the reviewed releases.
Adjusted series (company definition):
Sources: S1, S3, S4.
Margins (reported basis, computed):
Gross profit: MM's results releases do not report gross profit. Aggregator-derived gross figures are inconsistent across providers, so gross profit and gross margin are treated as not publicly disclosed in the reviewed primary sources.
Revenue CAGR (computed):
-
FY2021–FY2025: +6.1% a year, driven entirely by the 2021–22 acquisitions.
-
FY2022–FY2025: -6.0% a year, reflecting price deflation in board and the TANN disposal.
Below operating profit, FY2025:
-
Financial income: EUR 16.5 m (FY2024: EUR 27.1 m).
-
Financial expenses: EUR -53.4 m (FY2024: EUR -82.9 m).
-
Other financial result: EUR -38.5 m (FY2024: EUR -19.9 m), mainly FX.
-
Tax: EUR -68.7 m, an effective rate of 47.2%, driven by reversal of capitalised loss carryforwards at Board & Paper (FY2024: 3.4%, flattered by capitalisation of former Essentra loss carryforwards).
Quarterly trajectory
H1 2026 group results:
-
Sales: EUR 1,849.3 m (pro forma -4.7%).
-
Adjusted EBITDA: EUR 200.2 m (pro forma -3.5%, +6.6% versus H2 2025).
-
Reported operating profit: EUR 66.9 m, after EUR 22.9 m of Fit-For-Future one-offs.
-
Profit for the period: EUR 31.2 m. EPS: EUR 1.60.
-
Operating cash flow: EUR 145.1 m. Free cash flow: EUR 37.0 m. Capex: EUR 111.8 m.
-
Effective tax rate: 32.0%.
Balance sheet
Sources: S5 (FY2021–22) and S1 (FY2024–25).
Sources: S1, S3, S4, S5.
Other balance-sheet items:
Source: S1. The FY2024 figures include TANN cash and financial liabilities; balance-sheet values after reclassification were EUR 1,628.7 m and EUR 520.9 m.
Short-/long-term debt split: described only as "mainly long-term". The exact split is not publicly disclosed in the reviewed releases.
- The aggregator tangible book value per share fell sharply after the 2021–22 acquisitions, indicating material goodwill.
Working capital: a working-capital increase drove the FY2025 drop in operating cash flow. An absolute net working capital figure is not publicly disclosed in the reviewed releases.
Cash flow
Sources: S1, S3, S4, S5. The FY2022 D&A figure includes impairments.
Shareholder returns:
-
Share buybacks: zero in FY2021–24 (no programme disclosed). FY2025: EUR 41.2 m (569,019 shares).
-
Total cash dividends paid: not separately retrieved. DPS is shown in 6.1.
Guidance and planned spend:
-
2026 capex guided at about EUR 250 m.
-
Annual maintenance standstills cost about EUR 36 m in 2025 and about EUR 40 m guided for 2026, of which about EUR 35 m falls in Q3 2026.
Ratios
Ratio notes:
-
FY2021–22 ROCE is reported ROCE; FY2024–25 is adjusted ROCE. ROE for FY2021–22 and FY2024–25 is company-reported. ROA, asset turnover and net debt/equity are computed.
-
Net debt/equity was reported at 0.6 and net debt/EBITDA at 2.8.
-
Interest coverage, operating profit / financial expenses (computed):
-
FY2024: 2.3x (190.0 / 82.9).
-
FY2025: 4.1x reported (221.0 / 53.4) or 3.7x adjusted (195.4 / 53.4).
-
-
Debt/equity, financial liabilities / equity (computed): 0.77x in FY2024 and 0.67x in FY2025.
-
Current ratio: about 1.8x on aggregator balance-sheet data (current assets EUR 1.48 bn / current liabilities EUR 0.83 bn, S17).
-
Cash conversion cycle: not publicly disclosed.
-
Dividend-policy leverage corridors: net debt/equity 35–55% and net debt/adjusted EBITDA 1.5–2.5x. At end-2025 MM was at 43% and 2.2x.
Commentary on trends, inflections and drivers
FY2021–22: acquisition-led step change.
-
Kwidzyn and Kotkamills (consolidated from August 2021) and Essentra Packaging (from late 2022) lifted sales 52.5% in FY2022.
-
A tight board market and price pass-through of an energy shock pushed reported EBITDA to EUR 729.9 m and operating profit to EUR 510.3 m.
-
Net debt rose to EUR 1,481.5 m, financed largely through Schuldschein loans.
-
This was peak earnings.
FY2023: cyclical collapse.
-
Destocking and falling board prices cut adjusted EBITDA 41.5% to EUR 450.2 m. Net profit fell 74% to EUR 89.1 m.
-
Management responded with a profit and cash protection plan focused on working-capital release and capex restraint.
-
The result was record operating cash flow of EUR 786.2 m and free cash flow of EUR 369.8 m, which cut net debt to EUR 1,261.9 m. This was the first deleveraging inflection.
FY2024: trough-level margins, continued deleveraging.
-
Adjusted EBITDA fell a further 7% to EUR 418.5 m. Board & Paper posted an adjusted operating loss of EUR 19.2 m.
-
Strong Q4 cash generation reduced net debt to EUR 1,078.7 m.
FY2025: portfolio and cost reset.
-
The TANN sale (EUR 360 m EV) removed a high-margin but non-core business. Group adjusted EBITDA was flat at EUR 418.2 m, but pro forma it grew 7.9%, driven by Fit-For-Future savings (about EUR 70 m) and the Board & Paper turnaround to breakeven.
-
Reported net profit fell to EUR 77.0 m because of the Kolicevo impairment and a 47% tax rate.
-
Free cash flow almost disappeared (EUR 11.1 m) on working-capital outflows.
H1 2026: earnings stabilise, cash recovers.
-
Pro forma adjusted EBITDA (EUR 200.2 m) was almost flat year on year despite lower board prices and Middle East-related cost inflation.
-
Operating cash flow swung from EUR -103.3 m to EUR +145.1 m.
-
The key inflection to watch is whether Fit-For-Future (more than EUR 330 m cumulative by 2027) can outrun price deflation in board.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Division Overview
| Division | Board responsibility (from 1 Sep 2026) | Contents |
|---|---|---|
MM Food & Premium Packaging (FPP) | Roman Billiani | Folding cartons for food, confectionery, cereals, frozen foods, beverages, premium/luxury consumer goods and tobacco. Included TANN tipping paper until 2 Jun 2025. |
MM Pharma & Healthcare Packaging (PHP) | Andreas Koppitz | Pharma folding cartons, leaflets, labels and booklet labels. Sites in Western Europe (France, Spain, Ireland, Italy, UK, Nordics, etc.) and the US. |
MM Board & Paper (B&P) | Alexander Loimayr | Recycled-fibre cartonboard (WLC), virgin-fibre FBB/SBB, coated liner, uncoated fine paper, kraft papers, chemical pulp and CTMP |
Revenue by Segment
| Segment | FY2024 | FY2025 |
|---|---|---|
Food & Premium Packaging sales (EUR Mn) | 1,702.4 | 1,538.4 |
Food & Premium Packaging excl. TANN sales (EUR Mn) | 1,488.7 | 1,449.7 |
Pharma & Healthcare Packaging sales (EUR Mn) | 615.7 | 618.3 |
Board & Paper sales (EUR Mn) | 1,954.3 | 1,930.2 |
Group consolidated sales (EUR Mn) | 4,079.6 | 3,885.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansResults by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
FPP adjusted EBITDA (EUR Mn) | 258.3 | 228.2 |
FPP adjusted operating profit (EUR Mn) | 179.4 | 157.3 |
FPP adjusted operating margin (%) | 10.5 | 10.2 |
FPP excl. TANN adjusted EBITDA (EUR Mn) | 206.2 | 205.4 |
FPP excl. TANN adjusted operating profit (EUR Mn) | 139.4 | 134.5 |
PHP adjusted EBITDA (EUR Mn) | 69.9 | 77.7 |
PHP adjusted operating profit (EUR Mn) | 29.8 | 37.2 |
PHP adjusted operating margin (%) | 4.8 | 6.0 |
B&P adjusted EBITDA (EUR Mn) | 90.3 | 115.0 |
B&P adjusted operating profit (EUR Mn) | -19.2 | 3.4 |
B&P adjusted operating margin (%) | -1.0 | 0.2 |
Division Overview — FPP
| Division | Sales YoY % | Adj. EBITDA YoY % | Share of group sales (gross, %) | Adj. ROCE % | Capital employed EUR Mn | Capex EUR Mn |
|---|---|---|---|---|---|---|
FPP (reported) | -9.6 | -11.6 | 39.6 | 15.4 | 1,018.8 | 68.1 |
FPP excl. TANN | -2.6 | -0.4 | 37.3 | 14.3 | 937.4 | 64.4 |
PHP | +0.4 | +11.2 | 15.9 | 8.3 | 449.9 | 44.2 |
B&P | -1.2 | +27.2 | 49.7 | 0.2 | 1,888.7 | 123.1 |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | H1 2025 | H2 2025 | H1 2026 |
|---|---|---|---|
FPP excl. TANN sales (EUR Mn) | 724.6 | 725.1 | 684.0 |
FPP excl. TANN adjusted EBITDA (EUR Mn) | 97.0 | 108.4 | 97.9 |
FPP excl. TANN adjusted EBITDA margin (%) | 13.4 | 14.9 | 14.3 |
PHP sales (EUR Mn) | 320.8 | 297.5 | 318.8 |
PHP adjusted EBITDA (EUR Mn) | 40.1 | 37.6 | 45.6 |
PHP adjusted EBITDA margin (%) | 12.5 | 12.7 | 14.3 |
B&P sales (EUR Mn) | 1,000.1 | 930.1 | 940.4 |
B&P adjusted EBITDA (EUR Mn) | 70.3 | 44.7 | 56.8 |
B&P adjusted EBITDA margin (%) | 7.0 | 4.8 | 6.0 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (EUR Mn) | 3,069.7 | 4,682.1 | 4,164.4 | 4,079.6 | 3,885.3 |
Revenue growth YoY (%) | 21.4 | 52.5 | -11.1 | -2.0 | -4.8 |
EBITDA, headline basis (EUR Mn) | 421.0 | 729.9 | 450.2 | 418.5 | 418.2 |
Operating profit, reported (EUR Mn) | 269.6 | 510.3 | 197.6 | 190.0 | 221.0 |
Profit before tax (EUR Mn) | 244.5 | 466.9 | 136.7 | 114.3 | 145.7 |
Net profit / profit for the year (EUR Mn) | 190.7 | 345.2 | 89.1 | 110.5 | 77.0 |
EPS basic (EUR) | 9.46 | 17.19 | 4.36 | 5.41 | 3.86 |
Dividend per share (EUR) | 3.50 | 4.20 | 1.50 | 1.80 | 2.00 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Adjusted EBITDA (EUR Mn) | 769.0 | 450.2 | 418.5 | 418.2 |
Adjusted operating profit (EUR Mn) | 562.4 | 229.2 | 190.0 | 195.4 |
Adjusted EBITDA margin (%) | 16.4 | 10.8 | 10.3 | 10.8 |
Adjusted operating margin (%) | 12.0 | 5.5 | 4.7 | 5.0 |
Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EBITDA margin, headline basis (%) | 13.7 | 15.6 | 10.8 | 10.3 | 10.8 |
Operating margin, reported (%) | 8.8 | 10.9 | 4.7 | 4.7 | 5.7 |
Net margin (%) | 6.2 | 7.4 | 2.1 | 2.7 | 2.0 |
Income Statement and Margin Analysis (%) (FY2024–FY2025)
| Metric | FY2024 | FY2025 |
|---|---|---|
Sales excl. TANN (EUR Mn) | 3,866.0 | 3,796.6 |
Adjusted EBITDA excl. TANN (EUR Mn) | 366.5 | 395.4 |
Adjusted operating profit excl. TANN (EUR Mn) | 150.1 | 172.5 |
Adjusted EBITDA margin excl. TANN (%) | 9.5 | 10.4 |
Financial Analysis
| Item | Operating profit, EUR Mn | EBITDA, EUR Mn |
|---|---|---|
Gain on sale of TANN Group (FPP) | +125.1 | +125.1 |
Impairment MM Kolicevo (B&P) | -70.5 | — |
Fit-For-Future restructurings: PHP footprint optimisation | -15.2 | -13.6 |
Fit-For-Future restructurings: other | -13.8 | -12.7 |
Net one-offs | +25.6 | +98.8 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|
Group sales (EUR Mn) | 1,042.6 | 987.4 | 949.5 | 905.8 | 927.5 | 921.8 |
Group adjusted EBITDA (EUR Mn) | 119.3 | 111.2 | 89.8 | 97.9 | 104.1 | 96.1 |
Group adjusted operating profit (EUR Mn) | 61.0 | 55.7 | 35.2 | 43.5 | 49.1 | 40.7 |
Group adjusted EBITDA margin (%) | 11.4 | 11.3 | 9.5 | 10.8 | 11.2 | 10.4 |
Pro forma excl. TANN adjusted EBITDA (EUR Mn) | 104.8 | 102.6 | 90.0 | 98.0 | 104.1 | 96.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Total assets (EUR Mn) | 4,014.2 | 4,818.6 | 4,863.1 | 4,477.8 |
Total equity (EUR Mn) | 1,661.9 | 1,959.4 | 2,128.7 | 2,103.6 |
Equity ratio (%) | 41.4 | 40.7 | 43.8 | 47.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansKey Financials and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net debt (EUR Mn) | 1,063.5 | 1,481.5 | 1,261.9 | 1,078.7 | 913.7 |
Net debt / EBITDA, company basis (x) | 2.1 | 2.0 | 2.8 | 2.6 | 2.2 |
Balance Sheet
| Item | FY2024 | FY2025 |
|---|---|---|
Financial liabilities (mainly long-term), EUR Mn | 1,631.1 | 1,412.1 |
Cash available, EUR Mn | 552.4 | 498.4 |
Undrawn committed credit lines, EUR Mn | 361.0 | 351.3 |
Cash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (EUR Mn) | 269.8 | 299.7 | 786.2 | 516.3 | 231.1 |
Cash Flow (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Free cash flow, company definition (EUR Mn) | -19.7 | 369.8 | 302.2 | 11.1 |
Cash Flow — Capital expenditures
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
Capital expenditures (EUR Mn) | 257.8 | 345.1 | 220.9 | 232.7 |
Depreciation and amortisation (EUR Mn) | 151.4 | 219.6 | 228.0 | 219.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
ROE, company (%) | 11.9 | 19.1 | 5.3 | 3.6 |
ROA, net profit / total assets (%) | 4.8 | 7.2 | 2.3 | 1.7 |
Asset turnover (x) | 0.76 | 0.97 | 0.84 | 0.87 |
Net debt / equity (x) | 0.64 | 0.76 | 0.51 | 0.43 |
Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|
ROCE / adjusted ROCE (%) | 12.8 | 16.3 | 5.6 | 5.8 |
Geographic Revenue
| Indicator | Value | Source |
|---|---|---|
Share of B&P folding-carton board sales volume in Europe | More than 90% (H1 2026); overseas business deliberately reduced | S2 |
Middle East packaging plants, share of group sales (FY2025) | About 2% | S1 |
Middle East packaging plants, share of group adjusted EBITDA (FY2025) | About 6% | S1 |
PHP growth regions (H1 2026) | North America and Ireland, versus subdued individual Western/Central European markets | S2 |
PHP growth region (FY2025) | Solid growth in the United States | S1 |
TANN sites divested (2025) | Austria, China, the Philippines, Turkey, Canada, Germany | S10 |
Margin Analysis (%) (FY2022–FY2025)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Annual share price performance (%) | -12.99 | -17.44 | -37.20 | 17.71 |
Share Price & Returns
| Horizon (as of 15 Jan 2026, price EUR 92.70) | Performance |
|---|---|
1 year | +22.6% |
3 years | -40.1% |
5 years | -44.1% |
10 years | -11.4% |
Valuation Multiples
| Multiple | Basis | Value |
|---|---|---|
Market capitalisation | EUR 82 × 19.43 m | About EUR 1.59 bn |
Enterprise value | Market cap + FY2025 net debt (EUR 913.7 m); minorities, leases and pensions ignored | About EUR 2.51 bn |
P/E | FY2025 EPS EUR 3.86 | About 21x (aggregators show 20–22x, S17) |
EV / adjusted EBITDA | FY2025 adjusted EBITDA EUR 418.2 m | About 6.0x |
EV / sales | FY2025 sales EUR 3,885.3 m | About 0.65x |
P/B | FY2025 equity EUR 2,103.6 m | About 0.76x (aggregators: about 0.72x, S17) |
Dividend yield | DPS EUR 2.00 | About 2.4% |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share (EUR) | 3.50 | 4.20 | 1.50 | 1.80 | 2.00 |
Payout ratio (DPS / EPS, %) | 37.0 | 24.4 | 34.4 | 33.3 | 51.8 |
Capital Programmes
| Programme | Authorisation | Executed | Average price | Value |
|---|---|---|---|---|
3 Jan – 23 Dec 2025 | AGM 24 Apr 2024 (Section 65(1) no. 8 Austrian Stock Corporation Act). Up to 1 m shares (5%); price range EUR 10–80. | 569,019 shares (2.85%) | EUR 72.45 | EUR 41.2 m |
Analyst Conclusions
Management guidance (latest, 20 Aug 2026; S2)
H2 2026 environment: continued difficult conditions, with subdued consumer demand and higher transport, energy, chemical, wood and recovered-paper costs.
Q3 2026: operating profit burdened by about EUR 35 m of maintenance standstills at Kwidzyn and Kotkamills.
Offsets: slightly better pricing for selected board and paper grades, continued growth in selected pharma and consumer applications, and more than EUR 100 m of Fit-For-Future contribution in H2.
Fit-For-Future: more than EUR 330 m cumulative uplift by 2027 versus 2024 (excl. TANN).
Investment contributions: Kwidzyn, Romania and US projects contribute from 2027. Arnsberg synergies follow after closing.
Capex: about EUR 250 m in 2026.
Consensus growth expectations
Aggregators indicate an expected revenue CAGR of about 1–2% over the next three years (alphaspread, Simply Wall St, S17). Price targets cluster around EUR 90–98.
Bull case
-
Self-help compounds.
-
Fit-For-Future is running well ahead of plan: EUR 175 m delivered by mid-2026, and the target was raised twice to more than EUR 330 m.
-
The Kwidzyn projects (about EUR 30 m a year) and Arnsberg synergies add further from 2027.
-
On a flat market, this could lift adjusted EBITDA well above the EUR 418 m FY2025 level.
-
-
Board & Paper has operating leverage to any price recovery.
-
Utilisation is at 87%, the order backlog is up to 195 kt, and European market-share gains have been made.
-
Each 1 percentage point of margin on about EUR 1.9 bn of sales is worth about EUR 19 m.
-
The division's EUR 1.85 bn capital base is in the valuation at below book (P/B about 0.75x).
-
-
The packaging franchises are under-appreciated.
-
FPP (excl. TANN) and PHP both generate about 14% EBITDA margins.
-
PHP is now growing profitably in the US, helped by GLP-1-related demand.
-
The new 40–60% payout policy and a 2.2x leverage ratio support rising distributions.
-
Bear case
-
Structural, not cyclical.
-
European FBB overcapacity, returning US exports, Asian imports and declining office paper may keep B&P returns near zero indefinitely.
-
The adjusted ROCE of -0.5% LTM and the EUR 70.5 m Kolicevo impairment suggest further write-downs or closures are possible.
-
-
Cost and geopolitical shocks.
-
The Middle East escalation affects plants that provide about 6% of adjusted EBITDA and inflates energy, transport and chemical costs.
-
Management itself warns of "earnings risks" in an industry with structural overcapacity.
-
-
Cash conversion and earnings quality.
-
FY2025 free cash flow was only EUR 11.1 m. Reported net profit (EUR 77 m) was below the dividend-plus-buyback capacity implied by policy.
-
Recurring "one-off" restructuring charges (EUR 29 m in 2025, EUR 22.9 m in H1 2026) and volatile tax rates blur the true earnings base.
-
FPP volumes are falling (-7.1% in H1 2026).
-
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| 5 Nov 2026 | Q3 2026 trading statement: size of the standstill impact, B&P pricing, Fit-For-Future run-rate |
| Q4 2026 | Closing of the Arnsberg acquisition; disclosure of price and synergies |
| Q4 2026 | Completion of the Kwidzyn digester; Romania expansion ramp-up |
| Q4 2026 – H1 2027 | European board price announcements (FBB and WLC) |
| Ongoing | Middle East plant operations and energy prices |
| Mar 2027 | FY2026 results: dividend under the new payout policy; possible further impairments; 2027 Fit-For-Future update |
| Spring 2027 | Kotka electric boilers commissioned |
| 2,027 | US pharma expansion contribution; any new buyback |
Analyst verdict
Mayr-Melnhof is a company in the middle of a credible but incomplete repair. The 2021–22 bet on virgin-fibre board (Kwidzyn, Kotkamills) was made at the top of the cycle. Since then the European board market has moved into structural oversupply, driving group adjusted EBITDA from EUR 769 m (FY2022) to about EUR 418 m (FY2024–25), with the board division earning roughly nothing on more than EUR 1.8 bn of capital.
What has changed in the past 18 months is management's response:
-
a decisive portfolio clean-up (the TANN sale at EUR 360 m EV, five plant exits);
-
a transformation programme that is visibly over-delivering, with EUR 175 m booked by mid-2026 against a target raised twice to more than EUR 330 m;
-
continued deleveraging, with net debt down to EUR 914 m and 2.2x EBITDA;
-
a more shareholder-friendly dividend framework.
The two packaging divisions, with about 14% EBITDA margins and FPP's mid-teens ROCE, are genuinely good businesses and would probably command higher multiples on a standalone basis.
Against this, the market is right to be sceptical about how much of the Fit-For-Future gain will reach the bottom line rather than being absorbed by price deflation in board and by cost shocks from the Middle East. H1 2026 showed exactly this: adjusted EBITDA fell slightly despite EUR 105 m of savings. Weak 2025 cash conversion and recurring restructuring charges also temper the quality of earnings.
At about 6x EV/adjusted EBITDA and about 0.75x book, the valuation already discounts a prolonged board trough. Upside requires either evidence that savings are translating into EBITDA growth from H2 2026, or a turn in board pricing. The Q3 2026 trading statement and the FY2026 results will be the decisive tests.
Overall stance: constructive but conditional. This is a self-help and recovery story with a valuation floor provided by the packaging franchises and the balance sheet. Conviction would rise materially on sustained B&P margin improvement and on free cash flow covering the dividend.
Market data from aggregators are indicative only. This document does not constitute investment advice.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Board tenure | Age | Background (verified) |
|---|---|---|---|---|
Peter Oswald | Chairman of the Management Board and CEO | Since 2020; reappointed to 31 May 2029 | 61 in Mar 2024 | Long-standing paper and packaging executive, formerly at Mondi. Responsible for Board & Paper on an interim basis from Dec 2024 until mid-2025. |
Franz Hiesinger | CFO | Since Oct 2017; reappointed 1 Oct 2025 – 30 Sep 2030 | 58 in Mar 2024 | Previously held senior MM roles in group reporting, accounting, risk management and legal/compliance/internal audit (S17 profile). |
Roman Billiani | Member; Food & Premium Packaging | Since 1 May 2024; term to 30 Apr 2027 | 50 in Mar 2024 | About 20 years in fibre-based packaging management. Previously Managing Director "Food & Specialities Packaging" in MM Packaging. |
Andreas Koppitz | Member; Pharma & Healthcare Packaging | Since 1 Sep 2026; 3-year term | 46 | Has led the Pharma & Healthcare Packaging division since 2022 |
Alexander Loimayr | Member; Board & Paper | Since 1 Sep 2026; 3-year term | 47 | Has led Board & Paper since mid-2025. |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
Mar 2024 | Oswald reappointed; Billiani added | Continuity during transformation |
11 Nov 2024 | Niels Flierman (ex-DS Smith Paper & Recycling head) appointed for B&P from Jan 2025 | Intended to strengthen board-mill turnaround expertise |
23 Dec 2024 | Flierman withdraws for personal reasons; Oswald covers B&P | Leadership gap at the weakest division |
May 2025 | Hiesinger reappointed to 2030 | Financial continuity |
Mid-2025 | Loimayr takes over B&P division leadership | Internal appointment |
27 Aug 2026 | Board expanded to five (Koppitz, Loimayr) | Response to group size and complexity; divisional heads given Board seats |
Major Shareholders
| Holder | Stake % |
|---|---|
FMR LLC (Fidelity) | 5.22 |
Erste Asset Management | 2.93 |
Capital Research and Management | 1.24 |
Massachusetts Financial Services | 0.76 |
Lazard Frères Gestion | 0.65 |
Norges Bank Investment Management | 0.55 |
Dimensional Fund Advisors | 0.54 |
Charles Schwab Investment Management | 0.21 |
Universal Investment | 0.18 |
Raiffeisen Kapitalanlage-Gesellschaft | 0.14 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning versus MM |
|---|---|---|
Recycled cartonboard (WLC) | Reno De Medici (R.D.M., Apollo-owned) | Europe's other major recycled-board producer. MM is buying RDM's Arnsberg operations. |
Recycled cartonboard (WLC) | Smurfit Westrock (European board mills) | Diversified paper-based packaging major |
Recycled cartonboard (WLC) | Various Iberian, Italian and German mid-sized mills | Fragmented capacity contributing to overcapacity |
Virgin-fibre FBB / SBB | Metsä Board (Finland) | Leading European FBB producer; directly exposed to the same import and capacity pressures |
Virgin-fibre FBB / SBB | Stora Enso (Packaging Materials) | Large Nordic board producer; added FBB capacity |
Virgin-fibre FBB / SBB | Holmen Iggesund | Premium SBB/FBB |
Virgin-fibre FBB / SBB | Graphic Packaging International (US) | US paperboard exporter; MM cites the return of US export volumes to Europe as a pressure factor |
Virgin-fibre FBB / SBB | Asian producers (e.g. Chinese FBB mills) | Rising import pressure |
Uncoated fine paper | Sylvamo, Mondi, The Navigator Company | MM's Kwidzyn UFP competes in a structurally declining market |
Food & premium folding cartons | Graphic Packaging International (incl. former AR Packaging Europe) | Largest folding-carton converter in Europe and the US |
Food & premium folding cartons | Smurfit Westrock (consumer packaging) | Integrated competitor |
Food & premium folding cartons | Van Genechten Packaging; Edelmann (consumer); regional independents | European mid-sized converters |
Pharma & healthcare packaging | August Faller | Pharma cartons, leaflets, labels |
Pharma & healthcare packaging | Edelmann Group | Pharma and healthcare packaging |
Pharma & healthcare packaging | Schreiner MediPharm; Körber (pharma packaging solutions) | Labels and pharma packaging technology |
Pharma & healthcare packaging | Regional printers (Western Europe and US) | Contributing to the intense competition MM cites in Western/Central Europe |
Peer Comparison FY2025
| Company | Latest FY revenue | Growth trend | Margin profile |
|---|---|---|---|
Mayr-Melnhof (FY2025) | EUR 3,885.3 m | -4.8% (pro forma -1.8%) | Adjusted EBITDA margin 10.8%; adjusted operating margin 5.0% |
Metsä Board | — | Under pressure from FBB overcapacity | — |
Smurfit Westrock | — | Merger-driven | — |
Recent Developments
Litigation, regulatory actions and large layoffs in the window: none material identified beyond the restructurings listed above.



